A Meta-Analysis on Randomised Controlled Clinical Trials Evaluating the Effect of the Dietary Supplement Chitosan on Weight Loss, Lipid Parameters and Blood Pressure

Overview

Journal Medicina (Kaunas)

Publisher MDPI

Specialty General Medicine

Date 2018 Dec 15

PMID 30545156

Citations 15

Authors

Cristina Moraru

Manuela Maria Mincea

Mirela Frandes

Bogdan Timar

Vasile Ostafe

Affiliations

Soon will be listed here.

Abstract

Erratic results have been published concerning the influence of the dietary supplement chitosan used as a complementary remedy to decrease the body weight of overweight and obese people. The published articles mention as secondary possible benefits of usage of chitosan the improvement of blood pressure and serum lipids status. We performed a meta-analysis evaluating body weight, body mass index, total cholesterol, high density lipoprotein cholesterol, low density lipoprotein cholesterol, triglycerides, systolic and diastolic blood pressure among overweight and obese patients. Searching MEDLINE, Cochrane up to December 2017 on clinical trials that have assessed the influence of chitosan used as a dietary supplement on overweight and obese patients. An additional study was identified in the References section of another meta-analysis. A total of 14 randomised control trials (RCT) were used to assess the effect on body weight, serum lipids and blood pressure. The usage of chitosan as a dietary supplement up to 52 weeks seems to slightly reduce the body weight (-1.01 kg, 95% CI: -1.67 to -0.34). Considering the other parameters studied, the most significant improvement was observed in systolic and diastolic blood pressure: -2.68 mm Hg (95% CI: -4.19 to -1.18) and -2.14 mm Hg (95% CI: -4.14 to -0.14) in favour of chitosan versus a placebo. Based on the meta-analysis realized with 14 RCT we concluded that the usage of chitosan as a dietary supplement can lead to a slight short- and medium-term effect on weight loss and to the improvement of serum lipid profile and cardiovascular factors.

Citing Articles

From Molecules to Mind: The Critical Role of Chitosan, Collagen, Alginate, and Other Biopolymers in Neuroprotection and Neurodegeneration.

Kruczkowska W, Galeziewska J, Grabowska K, Gromek P, Czajkowska K, Rybicki M Molecules. 2025; 30(5).

PMID: 40076240 PMC: 11901451. DOI: 10.3390/molecules30051017.

The effect of chitosan supplementation on liver function, hepatic steatosis predictors, and metabolic indicators in adults with non-alcoholic fatty liver disease: a randomized, double-blinded, placebo-controlled, clinical trial.

Mohsenpoor M, Parastouei K, Taghdir M, Akbarzadeh M, Abbaszadeh S, Abyazi Heris M J Health Popul Nutr. 2025; 44(1):60.

PMID: 40025618 PMC: 11872331. DOI: 10.1186/s41043-025-00797-3.

Marine-Derived Polysaccharides and Their Potential Health Benefits in Nutraceutical Applications.

Carrasqueira J, Bernardino S, Bernardino R, Afonso C Mar Drugs. 2025; 23(2).

PMID: 39997184 PMC: 11857343. DOI: 10.3390/md23020060.

Polycystic Ovary Syndrome and the Potential for Nanomaterial-Based Drug Delivery in Therapy of This Disease.

Shi M, Li X, Xing L, Li Z, Zhou S, Wang Z Pharmaceutics. 2025; 16(12.

PMID: 39771535 PMC: 11678845. DOI: 10.3390/pharmaceutics16121556.

Effect of Chitosan on the Number of in Saliva: A Meta-Analysis and Systematic Review.

Rona V, Bencze B, Kelemen K, Vegh D, Toth R, Koi T Int J Mol Sci. 2023; 24(20).

PMID: 37894948 PMC: 10607225. DOI: 10.3390/ijms242015270.

References

Pittler M, Abbot N, Harkness E, Ernst E . Randomized, double-blind trial of chitosan for body weight reduction. Eur J Clin Nutr. 1999; 53(5):379-81. DOI: 10.1038/sj.ejcn.1600733. View

Tai T, Sheu W, Lee W, Yao H, Chiang M . Effect of chitosan on plasma lipoprotein concentrations in type 2 diabetic subjects with hypercholesterolemia. Diabetes Care. 2000; 23(11):1703-4. DOI: 10.2337/diacare.23.11.1703a. View

. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser. 2001; 894:i-xii, 1-253. View

Ho S, Tai E, Eng P, Tan C, Fok A . In the absence of dietary surveillance, chitosan does not reduce plasma lipids or obesity in hypercholesterolaemic obese Asian subjects. Singapore Med J. 2001; 42(1):6-10. View

Ylitalo R, Lehtinen S, Wuolijoki E, Ylitalo P, Lehtimaki T . Cholesterol-lowering properties and safety of chitosan. Arzneimittelforschung. 2002; 52(1):1-7. DOI: 10.1055/s-0031-1299848. View

Gallaher D, Gallaher C, Mahrt G, Carr T, Hollingshead C, Hesslink Jr R . A glucomannan and chitosan fiber supplement decreases plasma cholesterol and increases cholesterol excretion in overweight normocholesterolemic humans. J Am Coll Nutr. 2002; 21(5):428-33. DOI: 10.1080/07315724.2002.10719246. View

Fontaine K, Redden D, Wang C, Westfall A, Allison D . Years of life lost due to obesity. JAMA. 2003; 289(2):187-93. DOI: 10.1001/jama.289.2.187. View

Bokura H, Kobayashi S . Chitosan decreases total cholesterol in women: a randomized, double-blind, placebo-controlled trial. Eur J Clin Nutr. 2003; 57(5):721-5. DOI: 10.1038/sj.ejcn.1601603. View

Ausar S, Morcillo M, Leon A, Ribotta P, Masih R, Vilaro Mainero M . Improvement of HDL- and LDL-cholesterol levels in diabetic subjects by feeding bread containing chitosan. J Med Food. 2004; 6(4):397-9. DOI: 10.1089/109662003772519985. View

10.

Mhurchu C, Poppitt S, McGill A, Leahy F, Bennett D, Lin R . The effect of the dietary supplement, Chitosan, on body weight: a randomised controlled trial in 250 overweight and obese adults. Int J Obes Relat Metab Disord. 2004; 28(9):1149-56. DOI: 10.1038/sj.ijo.0802693. View

11.

Mhurchu C, Dunshea-Mooij C, Bennett D, Rodgers A . Effect of chitosan on weight loss in overweight and obese individuals: a systematic review of randomized controlled trials. Obes Rev. 2005; 6(1):35-42. DOI: 10.1111/j.1467-789X.2005.00158.x. View

12.

Lehtimaki T, Metso S, Ylitalo R, Rontu R, Nikkila M, Wuolijoki E . Microcrystalline chitosan is ineffective to decrease plasma lipids in both apolipoprotein E epsilon 4 carriers and non-carriers: a long-term placebo-controlled trial in hypercholesterolaemic volunteers. Basic Clin Pharmacol Toxicol. 2005; 97(2):98-103. DOI: 10.1111/j.1742-7843.2005.pto_111.x. View

13.

Gerstein H, Capes S . Dysglycemia: a key cardiovascular risk factor. Semin Vasc Med. 2005; 2(2):165-74. DOI: 10.1055/s-2002-32040. View

14.

Guha S, Pal S, Chatterjee N, Sarkar G, Pal S, Guha S . Effect of chitosan on lipid levels when administered concurrently with atorvastatin--a placebo controlled study. J Indian Med Assoc. 2005; 103(8):418, 420. View

15.

Kaats G, Michalek J, Preuss H . Evaluating efficacy of a chitosan product using a double-blinded, placebo-controlled protocol. J Am Coll Nutr. 2006; 25(5):389-94. DOI: 10.1080/07315724.2006.10719550. View

16.

Berghofer A, Pischon T, Reinhold T, Apovian C, Sharma A, Willich S . Obesity prevalence from a European perspective: a systematic review. BMC Public Health. 2008; 8:200. PMC: 2441615. DOI: 10.1186/1471-2458-8-200. View

17.

Jull A, Ni Mhurchu C, Bennett D, Dunshea-Mooij C, Rodgers A . Chitosan for overweight or obesity. Cochrane Database Syst Rev. 2008; (3):CD003892. DOI: 10.1002/14651858.CD003892.pub3. View

18.

Cornelli U, Belcaro G, Cesarone M, Cornelli M . Use of polyglucosamine and physical activity to reduce body weight and dyslipidemia in moderately overweight subjects. Minerva Cardioangiol. 2009; 56(5 Suppl):71-8. View

19.

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6(7):e1000097. PMC: 2707599. DOI: 10.1371/journal.pmed.1000097. View

20.

Picot J, Jones J, Colquitt J, Gospodarevskaya E, Loveman E, Baxter L . The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation. Health Technol Assess. 2009; 13(41):1-190, 215-357, iii-iv. DOI: 10.3310/hta13410. View